HC Wainwright Issues Positive Estimate for PRLD Earnings

Prelude Therapeutics Incorporated (NASDAQ:PRLD) – Equities researchers at HC Wainwright raised their Q2 2026 earnings per share estimates for shares of Prelude Therapeutics in a research report issued on Wednesday, July 15th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.17) per share for the quarter, up from their prior estimate of ($0.23). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Prelude Therapeutics’ current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Prelude Therapeutics’ Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.16) EPS and FY2026 earnings at ($0.62) EPS.

Prelude Therapeutics (NASDAQ:PRLD) last released its earnings results on Tuesday, May 12th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.14. The firm had revenue of $4.58 million for the quarter, compared to the consensus estimate of $4.58 million.

A number of other research firms have also recently commented on PRLD. Weiss Ratings upgraded shares of Prelude Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 1st. D. Boral Capital started coverage on Prelude Therapeutics in a research report on Monday, May 4th. They set a “buy” rating and a $9.00 price target for the company. Finally, Zacks Research raised shares of Prelude Therapeutics to a “hold” rating in a report on Tuesday, April 28th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $7.67.

Prelude Therapeutics Price Performance

Shares of NASDAQ PRLD opened at $4.20 on Friday. The stock has a market cap of $334.51 million, a PE ratio of -4.20 and a beta of 0.95. The firm has a fifty day moving average price of $4.38 and a 200-day moving average price of $3.56. Prelude Therapeutics has a 1 year low of $0.75 and a 1 year high of $5.69.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC boosted its stake in shares of Prelude Therapeutics by 1.4% during the 1st quarter. Renaissance Technologies LLC now owns 275,200 shares of the company’s stock valued at $941,000 after buying an additional 3,900 shares during the last quarter. XTX Topco Ltd lifted its holdings in Prelude Therapeutics by 72.4% in the second quarter. XTX Topco Ltd now owns 42,573 shares of the company’s stock worth $34,000 after acquiring an additional 17,873 shares during the last quarter. AQR Capital Management LLC boosted its position in Prelude Therapeutics by 170.7% during the 1st quarter. AQR Capital Management LLC now owns 33,823 shares of the company’s stock valued at $26,000 after purchasing an additional 21,330 shares during the period. Shay Capital LLC boosted its holdings in shares of Prelude Therapeutics by 33.3% during the third quarter. Shay Capital LLC now owns 100,000 shares of the company’s stock valued at $144,000 after acquiring an additional 25,000 shares during the period. Finally, State Street Corp boosted its stake in Prelude Therapeutics by 30.4% during the 4th quarter. State Street Corp now owns 127,292 shares of the company’s stock valued at $369,000 after purchasing an additional 29,700 shares during the period. 79.72% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director David P. Bonita bought 2,815,315 shares of the firm’s stock in a transaction that occurred on Tuesday, April 21st. The shares were purchased at an average price of $4.44 per share, with a total value of $12,499,998.60. Following the purchase, the director owned 11,808,945 shares in the company, valued at approximately $52,431,715.80. The trade was a 31.30% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Orbimed Advisors Llc purchased 2,815,315 shares of the firm’s stock in a transaction on Tuesday, April 21st. The stock was acquired at an average cost of $4.44 per share, with a total value of $12,499,998.60. Following the transaction, the director directly owned 11,808,945 shares in the company, valued at $52,431,715.80. This trade represents a 31.30% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 49.20% of the stock is owned by insiders.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated is a clinical-stage precision medicine company focused on the discovery and development of small molecule therapies for genetically defined oncology targets. By leveraging a chemical biology approach, the company aims to deliver targeted treatments that address key drivers of cancer cell growth and survival. Prelude’s pipeline emphasizes novel inhibitors designed to engage molecular pathways validated by both preclinical and clinical evidence.

Among Prelude’s lead programs is PRT2527, a selective PI3K‐alpha/delta inhibitor in Phase 1 clinical trials for solid tumors harboring PIK3CA and other pathway mutations.